Last reviewed · How we verify
Semaglutide Treatment
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight.
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.
At a glance
| Generic name | Semaglutide Treatment |
|---|---|
| Sponsor | University Health Network, Toronto |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1. It stimulates pancreatic beta cells to release insulin in response to elevated blood glucose, delays stomach emptying to reduce postprandial glucose spikes, and acts on the brain to suppress appetite and increase satiety. These combined effects result in improved glycemic control and significant weight loss.
Approved indications
- Type 2 diabetes mellitus
- Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Hypoglycemia (when combined with insulin or sulfonylureas)
Key clinical trials
- MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease (NA)
- A Study of a Weight Loss Intervention in People With Endometrial Cancer (EARLY_PHASE1)
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy (PHASE1)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Efficacy and Safety of QLG1090 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes (PHASE3)
- Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide Treatment CI brief — competitive landscape report
- Semaglutide Treatment updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI